Disclaimer:All content on this platform is sourced from the internet and is provided for informational purposes only. None of the content represents the views of this site, nor does it constitute investment advice. Please exercise caution when investing.
Strategy rose nearly 6% in pre-market trading after MSCI stated it would not proceed with its plan to exclude digital asset firm Treasury from its index; biotech company Ventyx Biosciences surged more than 70% on reports that Eli Lilly is close to finalizing an acquisition of the company.
Strategy rose nearly 6% in pre-market trading after MSCI stated it would not proceed with its plan to exclude digital asset firm Treasury from its index; biotech company Ventyx Biosciences surged more than 70% on reports that Eli Lilly is close to finalizing an acquisition of the company.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice. If you find any violations, please Click to Report
Recommended Reading


